• Explore /
  • Videos & Slides
  • / A randomized phase II trial of adjuvant pembrolizumab versus observation following curative resection for stage I non-small cell lung cancer (NSCLC) with primary tumors between 1-4 cm: Big Ten Cancer Research Consortium BTCRC-LUN18-153.

A randomized phase II trial of adjuvant pembrolizumab versus observation following curative resection for stage I non-small cell lung cancer (NSCLC) with primary tumors between 1-4 cm: Big Ten Cancer Research Consortium BTCRC-LUN18-153.

Abstract Video & Slides Poster

Presenter

Greg Durm

Greg Andrew Durm, MD

Indiana University Melvin and Bren Simon Cancer Center

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Videos & Slides Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Track

Lung Cancer

Sub Track

Adjuvant Therapy

Clinical Trial Registration Number

NCT04317534

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr TPS8583)

DOI

10.1200/JCO.2021.39.15_suppl.TPS8583

Abstract #

TPS8583

Poster Bd #

Online Only

Abstract Disclosures

Similar Videos & Slides

Speaker: Joachim Aerts, MD, PhD

Speaker: Heather A. Wakelee, MD, FASCO

Speaker: Edward B. Garon, MD, MS

Speaker: Mary E.R. O'Brien, MD